Form 4: Enliven Therapeutics CFO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Benjamin Hohl, CFO of Enliven Therapeutics, executed options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 27, 2025, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 3,250 shares of common stock at a price of $2.48 per share.
- Simultaneously, Hohl sold 3,250 shares of common stock at a weighted average price of $20.4083, with individual sales prices ranging from $19.98 to $20.8818.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Hohl directly owns 13,000 shares of Enliven Therapeutics common stock and 142,806 stock options.
- The stock options vest over time, with the initial vesting occurring on August 2, 2022, and the remaining shares vesting in 36 equal monthly installments.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It indicates that the CFO is exercising stock options and selling shares, which is a common practice, especially under pre-arranged trading plans like Rule 10b5-1. The market will interpret this in the context of the company's overall performance and future prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of incentive.
- Rule 10b5-1 trading plans are a common mechanism for insiders to sell shares without raising concerns about trading on non-public information.
- The vesting schedule of the options (one-fourth initially, then monthly) is a typical arrangement to incentivize long-term commitment.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The impact on employees, customers, suppliers, and creditors is likely negligible.
Key Dates
| Date | Description |
|---|---|
| June 26, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| August 2, 2022 | Initial vesting date for one-fourth of the stock options |
| February 27, 2025 | Date of the reported transactions (option exercise and share sale) |
| August 2, 2031 | Expiration date of the stock options |
| March 3, 2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.